Compound Evidence File
#EC-2026-0302
Dutasteride
Filed under Oral Tablets. The bureau holds 140 laboratory returns for this compound from 48 distinct subjects. Scores below are per-subject aggregates; open a subject row for the underlying evidence.
Cross-Index
Subjects Shipping This Compound
48 SUBJECTS| Subject | Grade | Samples | Mean | Min | Max | First seen | Last seen |
|---|---|---|---|---|---|---|---|
| Shanghai ERP BiotechnologyCASE #VI-2026-0936 | A | 4 | 10.0 | 9.9 | 10.0 | 4 Nov 2025 | 20 Jun 2026 |
| QYAOBIOCASE #VI-2026-0861 | A | 4 | 10.0 | 9.9 | 10.0 | 27 Mar 2026 | 10 Jul 2026 |
| Flourishglobal PeptideCASE #VI-2026-0630 | A | 4 | 10.0 | 9.9 | 10.0 | 22 Apr 2026 | 7 Jul 2026 |
| Shanghai Wibson BiotechnologyCASE #VI-2026-0379 | A | 4 | 10.0 | 9.9 | 10.0 | 9 Apr 2026 | 8 May 2026 |
| GenScript PeptidesCASE #VI-2026-0860 | A | 4 | 10.0 | 9.9 | 10.0 | 18 May 2026 | 12 Aug 2026 |
| Sigma-AldrichCASE #VI-2026-0829 | A | 3 | 10.0 | 9.9 | 10.0 | 5 Mar 2026 | 28 Jul 2026 |
| JEEP PeptidesCASE #VI-2026-0457 | A | 2 | 10.0 | 10.0 | 10.0 | 24 Dec 2025 | 20 Jun 2026 |
| Chinese Peptide CompanyCASE #VI-2026-0184 | A | 2 | 10.0 | 10.0 | 10.0 | 12 Apr 2026 | 11 May 2026 |
| PolyPeptide GroupCASE #VI-2026-0143 | A | 2 | 10.0 | 10.0 | 10.0 | 19 Apr 2026 | 23 Apr 2026 |
| AsymchemCASE #VI-2026-0091 | A | 2 | 10.0 | 10.0 | 10.0 | 24 Jun 2026 | 5 Aug 2026 |
| The Naughty NeedleCASE #VI-2026-0432 | X | 1 | 10.0 | 10.0 | 10.0 | 25 Apr 2025 | 25 Apr 2025 |
| Pure Tested PeptidesCASE #VI-2026-0225 | X | 1 | 10.0 | 10.0 | 10.0 | 27 Feb 2025 | 27 Feb 2025 |
| Tianjin Finder Chemical TFCCASE #VI-2026-0693 | A | 7 | 9.9 | 9.9 | 10.0 | 14 Nov 2025 | 16 Apr 2026 |
| HomopeptideCASE #VI-2026-0760 | A | 5 | 9.9 | 9.9 | 10.0 | 25 May 2026 | 25 May 2026 |
| WuXi TIDESCASE #VI-2026-0335 | A | 5 | 9.9 | 9.9 | 10.0 | 21 Dec 2025 | 26 Jul 2026 |
| BachemCASE #VI-2026-0314 | A | 4 | 9.9 | 9.9 | 10.0 | 12 Mar 2026 | 9 Jul 2026 |
| Kerui PeptidesCASE #VI-2026-0626 | A | 4 | 9.9 | 9.9 | 10.0 | 5 Mar 2026 | 13 Jul 2026 |
| Hybio PharmaceuticalCASE #VI-2026-0065 | A | 4 | 9.9 | 9.9 | 10.0 | 10 Mar 2026 | 27 May 2026 |
| SinoPepCASE #VI-2026-0387 | A | 4 | 9.9 | 9.9 | 10.0 | 3 Apr 2026 | 14 Jun 2026 |
| Mokemei BiotechnologyCASE #VI-2026-0540 | A | 3 | 9.9 | 9.9 | 10.0 | 27 May 2026 | 1 Jul 2026 |
| Sangon BioCASE #VI-2026-0671 | A | 2 | 9.9 | 9.9 | 10.0 | 6 Apr 2026 | 13 Jun 2026 |
| Hubei JianxiangCASE #VI-2026-0048 | A | 2 | 9.9 | 9.9 | 10.0 | 13 Jan 2026 | 16 Apr 2026 |
| Shanghai Sigma AudleyCASE #VI-2026-0505 | A | 2 | 9.9 | 9.9 | 10.0 | 19 Mar 2026 | 24 Jul 2026 |
| Thermo Fisher ScientificCASE #VI-2026-0142 | A | 2 | 9.9 | 9.9 | 10.0 | 21 Dec 2025 | 8 Aug 2026 |
| AmbioPharmCASE #VI-2026-0177 | A | 2 | 9.9 | 9.9 | 10.0 | 14 Jun 2026 | 2 Aug 2026 |
| Shanghai Sigma Audley SSACASE #VI-2026-0486 | A | 3 | 9.1 | 8.9 | 9.5 | 24 May 2026 | 24 May 2026 |
| Nantong Guangyuan Chemical GYCCASE #VI-2026-0284 | A | 7 | 8.8 | 7.1 | 9.9 | 25 May 2026 | 25 May 2026 |
| Wuhan Wansheng Bio (WWB)CASE #VI-2026-0594 | A | 6 | 8.7 | 7.6 | 9.5 | 25 May 2026 | 25 May 2026 |
| UtherCASE #VI-2026-0902 | X | 6 | 8.7 | 6.7 | 10.0 | 9 Jun 2025 | 21 May 2026 |
| Simple PeptideCASE #VI-2026-0782 | X | 2 | 8.6 | 7.2 | 9.9 | 3 Jun 2025 | 17 May 2026 |
| PeptidologyCASE #VI-2026-0520 | X | 1 | 8.5 | 8.5 | 8.5 | 7 May 2025 | 7 May 2025 |
| Qingdao Sigma Chemical QSCCASE #VI-2026-0538 | A | 6 | 8.3 | 7.5 | 9.6 | 21 May 2026 | 21 May 2026 |
| Mai PeptideCASE #VI-2026-0769 | X | 4 | 8.1 | 7.4 | 9.5 | 13 Feb 2025 | 21 May 2026 |
| Glbiochem (Shanghai)CASE #VI-2026-0704 | A | 3 | 7.9 | 7.3 | 8.8 | 24 May 2026 | 24 May 2026 |
| PeptiLab ResearchCASE #VI-2026-0267 | X | 1 | 7.2 | 7.2 | 7.2 | 20 Jun 2025 | 20 Jun 2025 |
| Amino LairCASE #VI-2026-0413 | X | 1 | 7.2 | 7.2 | 7.2 | 14 Jan 2025 | 14 Jan 2025 |
| ZZQ PeptidesCASE #VI-2026-0550 | X | 1 | 7.1 | 7.1 | 7.1 | 2 Apr 2025 | 2 Apr 2025 |
| Shandong Shengyuan Peptide TechnologyCASE #VI-2026-0634 | X | 1 | 6.8 | 6.8 | 6.8 | 7 May 2025 | 7 May 2025 |
| ZhuoYan labCASE #VI-2026-0902 | X | 2 | 6.5 | 6.3 | 6.7 | 9 Jun 2025 | 19 Jan 2026 |
| Elite Research USACASE #VI-2026-0267 | X | 2 | 6.3 | 5.8 | 6.8 | 27 Feb 2025 | 26 Jan 2026 |
| SRY LabsCASE #VI-2026-0657 | X | 8 | 6.2 | 3.3 | 7.9 | 7 May 2025 | 21 May 2026 |
| Prime PeptidesCASE #VI-2026-0696 | X | 1 | 6.2 | 6.2 | 6.2 | 8 Jul 2025 | 8 Jul 2025 |
| Zhang TYCASE #VI-2026-0070 | X | 1 | 6.1 | 6.1 | 6.1 | 27 Feb 2025 | 27 Feb 2025 |
| PurePEPSCASE #VI-2026-0552 | X | 1 | 5.8 | 5.8 | 5.8 | 13 Jun 2025 | 13 Jun 2025 |
| Xingtai Lesda TechnologyCASE #VI-2026-0381 | X | 1 | 5.3 | 5.3 | 5.3 | 7 May 2025 | 7 May 2025 |
| Welon Peptide SolutionsCASE #VI-2026-0478 | X | 1 | 4.5 | 4.5 | 4.5 | 16 Mar 2025 | 16 Mar 2025 |
| Advanced Technology and IndustrialCASE #VI-2026-0133 | X | 1 | 0.0 | 0.0 | 0.0 | 7 May 2025 | 7 May 2025 |
| HK Fat CatCASE #VI-2026-0376 | X | 1 | 0.0 | 0.0 | 0.0 | 14 Jan 2025 | 14 Jan 2025 |
Open any subject to view the batch-level evidence for Dutasteride alone.